Genetic Ablation of Sarm1 Mitigates Disease Acceleration after Traumatic Brain Injury in the SOD1G93A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis
- 10 January 2025
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 97 (5) , 963-975
Abstract
Objective: Approximately 20% of familial cases of amyotrophic lateral sclerosis (ALS) are caused by mutations in the gene encoding superoxide dismutase 1 (SOD1). Epidemiological data have identified traumatic brain injury (TBI) as an exogenous risk factor for ALS; however, the mechanisms by which TBI may worsen SOD1 ALS remain largely undefined.Methods: We sought to determine whether repetitive TBI (rTBI) accelerates disease onset and progression in the transgenic SOD1G93A mouse ALS model, and whether loss of the primary regulator of axonal degeneration sterile alpha and TIR motif containing 1 (Sarm1) mitigates the histological and behavioral pathophysiology. We subjected wild‐type (n = 23), Sarm1 knockout (KO; n = 17), SOD1G93A (n = 19), and SOD1G93AxSarm1KO (n = 26) mice of both sexes to rTBI or sham surgery at age 64 days (62–68 days). Body weight and ALS‐deficit score were serially assessed up to 17 weeks after surgery and histopathology assessed in layer V of the primary motor cortex at the study end point.Results: In sham injured SOD1G93A mice, genetic ablation of Sarm1 did not attenuate axonal loss, improve neurological deficits, or survival. The rTBI accelerated onset of G93A‐SOD1 ALS, as indicated by accentuated body weight loss, earlier onset of hindlimb tremor, and shortened survival. The rTBI also triggered TDP‐43 mislocalization, enhanced axonal and neuronal loss, microgliosis, and astrocytosis. Loss of Sarm1 significantly diminished the impact of rTBI on disease progression and rescued rTBI‐associated neuropathology.Interpretation: SARM1‐mediated axonal death pathway promotes pathogenesis after TBI in SOD1G93A mice suggesting that anti‐SARM1 therapeutics are a viable approach to preserve neurological function in injury‐accelerated G93A‐SOD1 ALS. ANN NEUROL 2025;97:963–975Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (NS131756)
This publication has 50 references indexed in Scilit:
- Amyotrophic lateral sclerosis2023
- Chronic traumatic encephalopathy (CTE): criteria for neuropathological diagnosis and relationship to repetitive head impactsActa Neuropathologica, 2023
- SARM1 signaling mechanisms in the injured nervous systemCurrent Opinion in Neurobiology, 2021
- Sarm1 loss reduces axonal damage and improves cognitive outcome after repetitive mild closed head injuryExperimental Neurology, 2020
- SARM: From immune regulator to cell executionerBiochemical Pharmacology, 2019
- Cortical Neurotoxic Astrocytes with Early ALS Pathology and miR-146a Deficit Replicate Gliosis Markers of Symptomatic SOD1G93A Mouse ModelMolecular Neurobiology, 2018
- Pathological Modification of TDP-43 in Amyotrophic Lateral Sclerosis with SOD1 MutationsMolecular Neurobiology, 2018
- The IL-1β phenomena in neuroinflammatory diseasesJournal of Neural Transmission, 2017
- Characterization of early pathogenesis in the SOD1G93A mouse model of ALS: part I, background and methodsBrain and Behavior, 2013
- TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutationActa Neuropathologica, 2007